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Abstract
This translational study aimed at gaining insight into the effects of lenalidomide in acute myeloid leukemia (AML). Forty-one
AML patients aged 66 or older of the Swiss cohort of the HOVON-103 AML/SAKK30/10 study were included. After random-
ization, they received standard induction chemotherapy with or without lenalidomide. Bone marrow biopsies at diagnosis and
before the 2nd induction cycle were obtained to assess the therapeutic impact on leukemic blasts and microenvironment.
Increased bone marrow angiogenesis, as assessed by microvessel density (MVD), was found at AML diagnosis and differed
significantly between theWHO categories. Morphological analysis revealed a higher initial MVD in AMLwith myelodysplasia-
related changes (AML-MRC) and a more substantial decrease of microvascularization after lenalidomide exposure. A slight
increase of T-bet-positive TH1-equivalents was identifiable under lenalidomide. In the subgroup of patients with AML-MRC, the
progression-free survival differed between the two treatment regimens, showing a potential but not significant benefit of
lenalidomide. We found no correlation between the cereblon genotype (the target of lenalidomide) and treatment response or
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prognosis. In conclusion, addition of lenalidomide may be beneficial to elderly patients suffering from AML-MRC, where it
leads to a reduction of microvascularization and, probably, to an intensified specific T cell-driven anti-leukemic response.
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Introduction
Most individuals with acute myeloid leukemia (AML) are
older than 65 years upon diagnosis [1]. As the incidence of
unfavorable genetic alterations increases with age, the prog-
nosis of AML in the elderly is dismal and associated with the
worst median overall survival (OS) of all cancers in this age
group with nearly 80% of the patients died after 1 year [1, 2].
Aggravatingly, chemotherapeutic treatment remains challeng-
ing due to the rising incidence of comorbidities and the poorer
performance status of aged individuals. Although the devel-
opment of less toxic and more effective treatment options is of
utter interest, only modest progress has been achieved in clin-
ical outcomes of elderly AML patients in the last decade.
Based on its clinical activity in related disorders such as
myelodysplastic syndromes (MDS) and other hematologic
malignancies including multiple myeloma and follicular lym-
phoma [3–5], the orally active immune-modulatory drug
(IMiD) lenalidomide gathered attention as a novel anti-
neoplastic agent for the treatment of AML. Lenalidomide tar-
gets the omnipresent E3 ubiquitin ligase complex cereblon
[6], which mediates its effects on tumor cells and non-
neoplastic cells of the tumor microenvironment [7].
Lenalidomide activates cereblon’s ligase activity leading to
faster degradation of the transcription factors Ikaros and
Aiolos, which play an important role in the regulation of B-
and T cell development [7], and the casein kinase 1A1
(CK1alpha), which is a negative regulator of p53 [8].
CK1alpha is encoded by the CSNK1A1 gene, which can be
deleted or mutated in del(5q) MDS. In murine models,
haploinsufficiency of this gene leads to hematopoietic stem
cell expansion, whereas a complete loss induces stem cell
apoptosis by activation of p53, explaining at least partially
the effect of lenalidomide in del(5q) MDS [9]. In analogy,
Csnk1a1 knockdown in AML cell lines increases p53 activity
andmyeloid differentiation and results in selective elimination
of leukemic cells [10].
Furthermore, autoubiquitination (and thus degradation) of
wild-type cereblon is prevented by lenalidomide. In net terms,
lenalidomide has anti-proliferative effects particularly on ma-
lignant B-cells and stimulating effects on by-stander T cells
and natural killer (NK) cells, while promoting the production
of anti-inflammatory cytokines [7]. Next to this anti-
neoplastic and immune-modulatory effect, lenalidomide im-
pairs the secretion of the vascular endothelial growth factor
(VEGF) in the bone marrow stroma, eventually influencing
vessel density and other microenvironmental changes [11].
Recently, the HOVON/SAKK study group published their
data of the HOVON103 AML/SAKK 30/10 trial on the addi-
tion of lenalidomide to standard intensive treatment in elderly
patients with AML and high-risk MDS [12]. Unfortunately,
the study failed to show a clear benefit for those patients re-
ceiving additional lenalidomide, putting it in line with many
other surveys performed in the setting of AML in the elderly.
Here, we present a translational research analysis of the study
encompassing patients of the Swiss study cohort, for whom
bone marrow biopsies at study inclusion and—for the major-
ity of individuals—before the 2nd induction cycle were avail-
able. Our results suggest that addition of lenalidomide to in-
duction chemotherapy may be beneficial to elderly patients
suffering from AML with myelodysplasia-related changes
(AML-MRC).
Materials and methods
Patient cohort and treatment
Forty-one patients of the Swiss cohort of HOVON103 AML/
SAKK 30/10 trial were included in this translational research
study, of whom 20 were male and 21 female (Table 1). They
were all previously untreated, aged ≥ 66, had a WHO perfor-
mance score of ≤ 2, and amorphologically confirmed diagnosis
of de novo AML. Patients with acute promyelocytic leukemia
were not included. The patients’mean age at first diagnosis was
69 years (range 66 to 76). Clinical outcome parameters for this
study were progression-free survival (PFS) and overall survival
(OS). For further details, we refer to the HOVON/SAKK study
group publication on the clinical trial [12]. This study was
approved by the ethics committee of Northwestern
Switzerland (EKNZ BASEC 2016-01218).
To morphologically assess the therapeutic impact on blasts
and microenvironment, bone marrow biopsies were gained at
the time-point of diagnosis and, whenever possible, before the
beginning of the 2nd induction cycle.
Karyotypes were classified according to Grimwade et al.
[13] into three prognostically relevant groups (favorable, in-
termediate, adverse). Considering morphological and geneti-
cal criteria, patients were subgrouped into different diagnostic
categories, according to the current WHO classification of
tumors of hematopoietic and lymphoid tissues [14].
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As described inmore detail by Ossenkoppele et al. [12], the
patients randomly received either a standard remission induc-
tion regimen with or without lenalidomide. Of our cohort, 19
patients were assigned to the standard treatment arm (dauno-
rubicin 45mg/m2 days 1–3 and cytarabine 200mg/m2 days 1–
7 in cycle I; and cytarabine 1000 mg/m2 q 12 h days 1–6 in
cycle II), and 22 patients additionally received lenalidomide at
an assigned dose level (10 to 20 mg/day orally, days 1–21 of
each cycle) (Table 1).
Morphological, immunohistochemical, and molecular
work-up of bone marrow biopsies
Bone marrow biopsies at the time-point of diagnosis were
available in 39/41 cases. A second bone marrow biopsy,
which was obtained before the 2nd induction cycle, was avail-
able in 28/41 cases. The specimens were fixed in 4% formalin
and paraffin-embedded, followed by decalcification with eth-
ylenediaminetetraacetic acid (EDTA) [15]. Hematoxylin-and-
Table 1 Patients’ characteristics
and responses to treatment Standard treatment (n = 19): n(%) With lenalidomide (n = 22): n(%)
Sex
• Male 10 (52.6%) 10 (45.5%)
• Female 9 (47.4%) 12 (54.5%)
Dose of lenalidomide
• 15 mg NA 1 (4.5%)
• 20 mg NA 21 (95.5%)
WHO classification of AML
• AML NOS 10 (52.6%) 11 (50.0%)
• AML mutations 6 (31.6%) 4 (18.2%)
• AML specific translocations 2 (10.5%) 0 (0.0%)
• AML MRC 1 (5.3%) 7 (31.8%)
Age at registration (years)
• 66–70 13 (68.4%) 20 (90.9%)
• 71–76 6 (31.6%) 2 (9.1%)
Karyotype according to Grimwade
• Favorable 2 (10.5%) 0 (0.0%)
• Intermediate 15 (78.9%) 15 (68.2%)
• Adverse 0 (0.0%) 5 (22.7%)
• Missing 2 (10.5%) 2 (9.1%)
Best response after cycle 1
• CR 11 (57.9%) 11 (50.0%)
• CRi 0 (0.0%) 4 (18.2%)
• PR 3 (15.8%) 0 (0.0%)
• RD 3 (15.8%) 6 (27.3%)
• Death in aplasia 0 (0.0%) 1 (4.5%)
• Death of indeterminate cause 2 (10.5%) 0 (0.0%)
Did patient start cycle 2?
• No 4 (21.1%) 8 (36.4%)
• Yes 15 (78.9%) 14 (63.6%)
Best response after cycle 2 (only for patients started cycle 2)
• CR 12 8
• CRi 1 3
• PR 1 1
• RD 1 0
• death in aplasia 0 1
• death of indeterminate cause 0 1
NA, not applicable; NOS, not otherwise specified; MRC, myelodysplasia-related changes; CR, complete remis-
sion; CRi, CR with incomplete hematologic recovery; PR, partial remission; RD, refractory disease
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eosin- (H&E) and Gömöri-stained slides were reviewed, and
t h e p r e s en c e and amoun t o f l e uk em i c b l a s t s ,
myelodysplasia-related changes, and the degree of myelo-
fibrosis [16] were assessed. Immunohistochemistry was
performed using the automated s ta in ing sys tem
Benchmark XT (Roche/Ventana Medical Systems,
Tucson, USA). To evaluate microvessels, CD34 staining
was performed and scored as described [17], and in cases
with excessive amounts of CD34 positive blasts hamper-
ing quantification, supplemented by a CD31 staining.
Stem cell niches were quantified using a nestin staining
as previously shown [18]. Blast quantification was based
on morphological analysis of the H&E slides corroborated
by CD34 staining, if expressed by the tumor cells, and
correlated with the blast counts assessed on aspiration
smears. Erythropoiesis was investigated with the help of
E-cadherin. Characterization and quantification of B-, T-,
NK- cells, and monocytes were performed utilizing anti-
bodies against CD3, CD4, CD8, CD20, CD56, CD57,
FoxP3, granzyme B, PD1, PD-L1, TIA1, and T-bet as de-
scribed [19, 20]. Lenalidomide’s target cereblon has also
been stained for and was assessed depending on its inten-
sity: a quality score from 0 (negative) to 3 (strong, un-
equivocal positivity) has been assigned. To highlight vas-
cular endothelial growth factor (VEGF) and -receptor
(VEGFR) expression alterations, stainings for VEGF and
VEGFR2 were performed [17]. Antibody sources, dilu-
tions, incubation, and retrieval conditions as well as cutoff
scores are displayed in Table 2. Two authors (MMB and
AT) investigated all stained slides, and reproducibility was
estimated applying the Cronbach’s Alpha method.
Cereblon genotyping
DNA was extracted from 34 available bone marrow biopsies
at the time of first diagnosis using the GeneReadTM DNA-
FFPE-Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. Fifty nanograms of the extracted DNA
was used to determine the rs1672753 (A/G) polymorphism
located in the 5′ UTR of CRBN. Genotyping was performed
using the Biorad QX200 digital PCR platform (Bio-Rad,
Berkeley, CA, USA).
Statistical analysis
All statistical analyses were performed with the IBM SPSS
25.0 (IBM, Armonk, New York) and R version 3.5.3. The
degree of inter-observer consensus was evaluated by interclass
correlation coefficients, using reliability Cronbach’s Alpha
analysis, α values > 0.75 indicating a good agreement [21].
Comparisons were performed using the Kruskal–Wallis- or
the Mann–Whitney U (MWU)–tests. Wilcoxon signed rank
test was used to compare numeric variables between pre- and
post-treatment. To investigate the correlation between two
markers, Spearman rank correlation coefficient (ρ) was esti-
mated; only the estimated ρ > 0.40 were further considered.
The 95% confidence interval (CI) of ρwas based on bootstrap
method. Progression-free survival (PFS) was defined as the
time from registration until relapse or death, whichever oc-
curred earlier. Overall survival (OS) was defined as time from
registration until death. These time-to-event endpoints were
analyzed using 50 ng Kaplan-Meier estimate, and 95% CI of
its median was based on log transformation. Generally, log
rank test was used to compare time-to-event endpoints be-
tween groups. However, if a small group (group size ≤ 2)
was involved, permutation test was used. Cox proportional
hazards regression model was used to investigate the associa-
tion between time-to-event endpoints and continuous vari-
ables. If the distribution of continuous variable is not symmet-
ric, it will be log transformed before modelling. P values <
0.05 were considered as significant. Two-sided tests were
used throughout. All results were not corrected for multiple
testing.
Results
Patient cohort and treatment
Patients’ baseline characteristics are shown in Table 1.
Regarding the karyotype analysis according to Grimwade,
two patients were categorized as having a favorable karyo-
type, five patients had a karyotype with adverse prognostic
impact and the karyotype of 30 patients was classified as in-
termediate; in 4 patients, this information was missing.
Patients were assigned to the treatment arms irrespective of
their karyotype. Due to the random distribution, all patients
with a favorable karyotype were allocated in the standard
treatment arm, whereas all patients with an unfavorable kar-
yotype received additional lenalidomide. The 30 patients with
intermediate karyotype were distributed equally between both
treatment groups.
According to the WHO classification 2017, 21 patients
were categorized as AML, not otherwise specified (NOS)
(AML, NOS). Of these, ten received standard treatment and
eleven additional lenalidomide. AMLwith defining mutations
(NPM1, FLT3, or CEBPA) applied to 10 patients, of whom 4
received lenalidomide and 6 did not. Specific translocations or
inversions were found in another 2 patients [inv(16) or
t(16;16)], who were assigned to the category AML with de-
fining translocations; both patients underwent standard treat-
ment. The AML category with myelodysplasia-related chang-
es (AML-MRC), either histomorphologically or genetically,
applied to 8 patients; 7 of them were treated with additional
lenalidomide and only one with the standard regimen
(Table 1).
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Morphological, immunohistochemical, and molecular
work-up of pre- and post-treatment bone marrow
biopsies
Internal consistency analysis regarding evaluation of the im-
munohistochemical markers yielded good or excellent results
for myelofibrosis, nestin niches, CD34-positive blast counts,
and counting of granzyme B, T-bet, FoxP3, CD3, CD4, CD8,
and E-cadherin positive cells. Acceptable results were obtain-
ed for the analysis of microvessel density, PD-L1, CD20, and
CD57. The reproducibility of PD1 was estimated as question-
able and was poor for TIA1, and therefore no further analyses
linked to this latter marker were done. CD56 staining never
yielded positive cells, except for osteoblasts.
All applied immunohistochemical markers were analyzed
regarding their distribution among the individual WHO cate-
gories, their prognostic impact, and under consideration of the
administered therapy (Fig. 1 and Supplementary Table 1).
Here, only potentially relevant results are described.
Blasts
Irrespectively of the therapeutic regimes, the amount of
blasts significantly decreased after treatment: from
45.4% (± 26.7) to 9.2% (± 21.7) in the standard arm vs.
51.9% (± 25.0) to 17.0% (± 20.8) in the lenalidomide arm
(p = 0.001 and 0.004, respectively), (Supplementary
Figure 1A-D; Fig. 2a–d); without significant difference
of the drops between both treatment arms. With the de-
crease of blasts, morphological regeneration of the bone
marrow with relative increase of adipocytes was detectible
(Supplementary Figure 1A-B; Fig. 2a, b). When comparing
both treatment regimens with respect to the WHO category,
addition of lenalidomide was associated with a more sub-
stantial decrease of blasts, particularly in patients with
AML with defining mutations (66.7% ± 14.5) compared
to standard treatment (24% ± 20.2; p = 0.034), while in all
other subgroups it was comparable between both treatment
arms.
Microvessel density
Previously, we could show that the bone marrow microvessel
density (MVD; given per mm2), is significantly higher in
newly diagnosed AML compared to healthy control individ-
uals [22]. The current study furthermore showed a significant
difference between the MVD of the various AML WHO cat-
egories (p = 0.011), being highest in AML-MRC (Fig. 2c)
Table 2 Antibodies applied and cut-off scores
Antibody Source and clone or ID Dilution Scoring/counting
Cereblon Celgene Corporation 1:400 Moderate to strong expression in > 50% of tumor cells
CD3 Ventana 790-4341 Ready to use Any lymphocyte, finally scored as % positive cells/all cells
CD4 Cell Marque SP35 1:100 Any lymphocyte, finally scored as % positive cells/all cells
CD8 DAKO C8/144B 1:400 Any lymphocyte, finally scored as % positive cells/all cells
CD20 Ventana QBEnd/10 Ready to use Any lymphocyte, finally scored as % positive cells/all cells
CD31 Ventana 760-4378 rReady to use Any lymphocyte, finally scored as % positive cells/all cells
CD34 Ventana 790-2927 Ready to use Any microvessel and any blast, finally scored as Nmicorvessels/mm2 or % positive
blasts/all cells
CD56 Ventana 790-4465 Ready to use Any lymphocyte, finally scored as % positive cells/all cells
CD57 Ventana 760-2626. Ready to use Any lymphocyte, finally scored as % positive cells/all cells
E-cadherin Ventana EP700Y Ready to use Any erythropoietic cells, finally scored as % positive cells/all cells
FoxP3 Abcam mAbcam 22510 1:50 Any lymphocyte, finally scored as % positive cells/all cells
Granzyme B Novocastra 11F1 1:100 Any lymphocyte, finally scored as % positive cells/all cells
Nestin AbD Serotec 10C2 1:200 Any perivascular niche (either single cells or clusters of up to three cells), finally
scored as Nniches/mm2
PD1 Cell Marque NAT105 1:50 Any lymphocyte, finally scored as % positive cells/all cells
PDL1 Cell signaling E1L3N 1:50 Single+ cells, 1–5% + cells, or > 5% + mononuclear cells
T-bet Abcam ab154200 1:100 Any lymphocyte, finally scored as % positive cells/all cells
TIA1 Biocare CM130C 1:25 Any lymphocyte, finally scored as % positive cells/all cells
VEGF DAKO VG1 1:40 * Moderate to strong expression in > 50% of tumor cells
VEGFR2 Neomarkers RB-10453-P1 1:10 * Moderate to strong expression in > 50% of tumor cells
In all instances except for *, in which high pH buffers have been applied, respectively, antigen retrieval was based on lower pH buffers andmicrowaving
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(mean 28 ± 6.8; versus 14.9 ± 10.6 in AML, NOS
(Supplementary Figure 1C), versus 24 ± 10.7 in AML with
defining mutations, versus 9.5 ± 2.1 in AML with defining
translocations). The same was true for the drop of MVD
after treatment (p = 0.001), showing the most prominent
decrease in the WHO category AML-MRC (Fig. 2d) (mean
drop 19.5 ± 17.7; versus 9.0 ± 11.6 in AML with defining
mutations, versus increases in AML, NOS with 2.5 ± 9.3
(Supplementary Figure 1D) and in one evaluable AMLwith
defining translocations with 41.0). Due to an asymmetric
distribution of AML-MRC cases among the two treatment
arms (i.e., most cases being treated with additional
lenalidomide), the initial MVD was higher in the
lenalidomide treated group (24.9 ± 11.4 versus 14.5 ± 8.5;
p = 0.011) and – accordingly— under standard treatment
microvessels increased from 14.5 ± 8.5 to 17.2 ± 12, in
contrast to a reduction from 24.9 ± 11.4 to 12.8 ± 6.7 under
additional lenalidomide (p = 0.041) (Fig. 1).
Stem cell niches
The amount of nestin-positive stem cell niches was not mod-
ified under treatment, but their increased presence in the initial
biopsy seemed to possibly correlate with an adverse prognosis
regarding OS (hazard ratio: 1.75, 95% CI: 0.94–3.27; p =
0.076).
Erythropoiesis
Erythropoiesis (assessed by E-cadherin) increased in both
treatment arms, which was slightly more prominent with the
addition of lenalidomide (4.1 % versus 9.1 %; p = 0.12).
Fig. 1 Boxplot diagram
visualizing quantitative changes
of microvessel density (MVD)
and selected studied T cell
populations in acute myeloid
leukemia treated by either
standard chemotherapy (upper) or
standard chemotherapy and
additional lenalidomide (lower);
boxes are color coded according
to variables and pairwise grouped
before (pre) and after (post)
treatment. Note the considerably
more pronounced decrease of
MVD and the more limited
increase of T cells under
lenalidomide with the exception
of the T-bet-positive
subpopulation that seems to more
stringently increase with addition
of lenalidomide
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B-, T-NK- cells and monocytes
The distribution of B-, T-NK- cells, and monocytes did not
differ between the pre-treatment biopsies of both therapy
groups (Fig. 1). Referring to the individual WHO categories,
only the presence of granzyme-B-positive lymphocytes dif-
fered among the miscellaneous groups (p = 0.00962), being
highest in AML-MRC (mean positive cells 4.5% ± 3.9; versus
1.3% ± 1.5 in AML, NOS, versus 0.5% ± 0.7 in AML with
defining mutations, versus 2.5% ± 2.1 in AML with defining
translocations). Neither standard treatment nor addition of
lenalidomide caused a significant increase in T cells as
assessed with the pan-T cell marker CD3, but subtle changes
in the composition of the T cell subpopulations could be iden-
tified (Fig. 1). Under lenalidomide, the CD4 positive T cell
count remained stable, while it increased under standard treat-
ment by 6% ± 9.1 (versus 1.9% ± 3.2 under addition of
lenalidomide, p = 0.029; Fig. 1). The amount of CD8-
positive T cells did not significantly change under therapy
(Fig. 1, Fig. 2e–f, Supplementary Figure 1E-F). Importantly
Fig. 2. Pre- (left side) and post-
treatment (right side) bone
marrow biopsies of a male patient
suffering from acute myeloid
leukemia with myelodysplasia-
related changes, who has been
treated with chemotherapy and
additional lenalidomide. a
Conventional morphology at
initial diagnosis, H&E. b
Conventional morphology before
the second induction cycle, H&E.
c CD34 staining revealing higher
microvessel density and partial




staining of the post-treatment
biopsy before the second
induction cycle illustrating a
significant decrease of the
microvessels and complete
absence of positively staining
blasts and megakaryocytes,
immunoperoxidase. e, f
Increasing amount of CD8-
positive T cells from 2% pre-
treatment (e) to 15% post-
treatment (f), immunoperoxidase.
g, h Increasing amount of T-bet-
positive T-helper cells from 1%
pre-treatment (g) to 9% post-
treatment (h), immunoperoxidase
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with respect to T cell subpopulations, T-bet-positive T-helper
1 cells seemed to slightly increase under addition of
lenalidomide compared to the standard treatment (p = 0.063;
Fig. 1, Fig. 2g–h, Supplementary Figure 1G-H). In contrast,
amounts of FoxP3-positive regulatory T cells were not influ-
enced by either treatment arm. The same was observed for
CD57-positive T-large granular lymphocyte-equivalents.
Remarkably, the proportion of granzyme-B-positive cells—
either representing non activated (since TIA1-negative) cyto-
toxic T-cells or NK-cells—significantly increased under the
standard regimen (6.5% ± 6.9 vs. 0.7% ± 4.6 under addition of
lenalidomide, p = 0.019; Fig. 1). The increase of PD-1-
positive T-cells was not significant in neither treatment arm,
but it was slightly less pronounced under lenalidomide (0.2%
± 0.9) compared to the standard treatment (0.9% ± 1.0; p =
0.19).
Cereblon
Strong expression of cereblon in the leukemic blasts (Fig. 3)
was not linked to unfavorable OS (hazard ratio: 1.18, 95% CI:
0.85–1.65; p = 0.328).
Correlation analysis
The presence of T-bet-positive cells correlated with the pres-
ence of CD8-positive cells (p = 0.00004; ρ = 0.61, 95% CI
0.32–0.79), CD4-positive cells (p = 0.00007; ρ = 0.59, 95%
CI 0.37-0.74), CD57-positive cells (p = 0.001; ρ = 0.51, 95%
CI 0.21–0.71), and the expression of VEGFR2 (p = 0.002; ρ =
0.48, 95% CI 0.14-0.69). In turn, the expression of VEGFR2
correlated with the grade of myelofibrosis (p = 0.001; ρ =
0.53, 95% CI 0.25-0.71) and the presence of nestin-positive
stem cell niches (p = 0.001; ρ = 0.53, 95% CI 0.22-0.74).
Additionally, CD4-positive cells correlated with the presence
of granzyme-B-positive cells (p = 0.001; ρ = 0.55, 95% CI
0.25–0.74).
Genotype analysis of CRBN
Whether CRBN was homozygous wild type (26 instances) or
contained variant alleles (8 instances), did not have an impact
on the treatment effect or the prognosis, irrespective of the
therapy applied.
Outcome
The median OS of the cohort was 18.5 months (95% CI 8.–-
46.8, 30 events) and the median PFS 8.9 months (95%CI 6.4–
17.1, 34 events). Neither the OS, nor the PFS differed signif-
icantly between the two treatment arms, in accordance with
the results of Ossenkoppele et al. (12). Neither age nor gender
were relevant for clinical outcome. PFS was significantly in-
fluenced by the karyotype (p = 0.012) and highly significantly
by the WHO category (p = 0.0061), being shortest in AML-
MRC. In this category, the median PFS differed between the
patient, who received standard treatment (0.4 months), and the
remaining patients receiving additional lenalidomide (2.6
months; p = 0.25), yet this did not reach statistical signifi-
cance. As expected, the karyotype (p = 0.0042) and the
WHO category (p = 0.0030) had a significant impact on the
OS. Neither the amounts nor the dynamics of the various
studied T cell subpopulations correlated with prognosis.
Discussion
Despite extensive research efforts, the prognosis of AML—
especially in the elderly—remains poor. Therefore, more ef-
fective and better tolerable therapeutic strategies are of urgent
need. Lenalidomide, an immune-modulatory drug already
successfully implemented in other hematological malignan-
cies associated with intrinsic dysfunction of the bone marrow,
gathered attention as a potentially effective drug in AML.
Indeed, in an AMLmurine model, immune-modulatory drugs
were shown to hamper leukemia progression in vivo and to
induce enhanced allogenic NK-cell activity [23].
In this translational research study of the Swiss cohort of
HOVON103 AML/SAKK30/10, we were able to show per-
ceptible differences in the outcome of AML-MRC patients:
those with additional lenalidomide treatment had a longer PFS
compared to the AML-MRC patients treated with chemother-
apy alone. Unfortunately, a statistical significance was not
reached due to the low case numbers and the unfavorable
random distribution of patients between both treatment arms
(only one patient received standard chemotherapy and 7
Fig. 3. Cereblon staining of the same patient as in Fig. 2 from the time-
point of initial diagnosis showing a distinct strong expression of
lenalidomide’s target cereblon in all leukemic blasts and dysplastic
megakaryocytes. Note: cereblon-negative residual erythropoiesis and
isolated unremarkable megakaryocytes
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patients received additional lenalidomide). Nevertheless, pa-
tients with AML-MRC had a significantly higher bone mar-
row MVD compared to other AML categories and the most
prominent lenalidomide-induced decrease of microvessels.
Since it is known that a high bone marrowMVD is associated
with a poor prognosis and that the reduction of microvessels
correlates with treatment response [24, 25], we hypothesize
that this particular patient subgroup, i.e., AML-MRC, might
profit from the antiangiogenic effects of lenalidomide.
Consistently, AML blasts are known to depend on the pres-
ence of nestin-positive stem cell niches [26], the density of
which in turn correlated with the expression of the
neovascularization-promoting VEGFR2 in our cohort. In gen-
eral, myeloid malignancies such as AML can remodel stem
cell niches to support malignant growth and to sustain
stemness [27, 28]. Concordantly, in our study, therapy-
induced blast reduction was not reflected by numeric changes
of nestin-positive stem cell niches, yet an increased presence
of such niches was linked to adverse outcome with respect to
OS. If these niches represent a treatment-refractory place of
retreat of leukemic blasts remains to be determined.
At least in our study, the effect of lenalidomide in AML-
MRC was independent of the presence of del(5q), which has
been linked to a better susceptibility to lenalidomide treatment
in MDS [29]: the only patient of our cohort, who displayed
del(5q) (in the context of a complex karyotype) and fulfilled
the criteria of AML-MRC, received standard therapy.
Irrespectively of the AML category, subtle treatment-
induced changes in the composition of T cell subpopulations
were observed, although the total number of T cells did not
significantly differ between pre- and post-treatment biopsies.
Under lenalidomide, the amount of T-bet-positive T cells
more consistently increased, which might be interpreted as a
sign of increased T cell driven immune response against the
tumor cells. Indeed, the transcription factor T-bet has been
found to be one of the key players in the induction of
leukemia-reactive T-cells, and lower T-bet expression rates
have been linked to poor immune responses and disease pro-
gressions [30, 31]. Correspondingly, the presence of T-bet-
positive cells correlated, among others, with the presence of
CD8-positive cytotoxic T cell-equivalents and CD57-positive
large granular lymphocyte-equivalents.
The low PD-1-positive T cell count in all our samples fits to
the fact that immune-checkpoint inhibitor treatment failed to
achieve a major breakthrough in AML. This may be linked to
a lower immunogenic potential compared to solid tumors such
as melanoma or non-small cell lung cancer or due to genuine
impairment of the antigen processingmachinery in AML [32].
Nonetheless, we found a slight increase of PD-1-positive T
cells in the bone marrow biopsies after treatment, indicative
for a growing T cell exhaustion and enhanced inhibition of
anti-tumor immune response. Although not significant, this
effect seemed to be less pronounced under lenalidomide,
which leads us to hypothesize, that lenalidomide—as an
IMiD—may support some anti-leukemic immune responses.
This is in accordance with observations in other hematologic
malignancies such as multiple myeloma, in which
lenalidomide significantly reduces PD-1 surface expression
on T cells and enhances the anti-tumor response [33].
Additionally, lenalidomide was noticed to counteract the neg-
ative impact of PD-1-positive cells in follicular lymphoma
patients, potentially due to its stimulating effect on the im-
mune response [4].
The presence of cytotoxic, granzyme-B-positive T cells
differed between various AML categories of our study collec-
tive, being highest in AML-MRC. This observation is sup-
ported by recently published data, demonstrating an associa-
tion between cell-intrinsic genetic alterations in AML and the
amount of cytotoxic lymphocytes, suggesting that AML-
MRC may be more immunogenic. Indeed, genetic alterations
linked with poor prognosis [TP53, del(5q), complex karyo-
types] and being more frequently encountered in AML-MRC,
as well as AML-MRC per se were found to be associated with
higher T cell induced cytolytic activity [34].
Significant decrease of leukemic blasts under treatment
was observed in both arms. With respect to the AML-catego-
ries, a more substantial blast drop under lenalidomide was
noticed in AML with defining mutations, despite the fact that
the presence of driver mutations such as FLT3 and NPM1 has
been linked to low cytolytic activity of the tumor microenvi-
ronment [34]. If this effect is linked to the immunemodulatory
or other functions of lenalidomide and if it is reproducible in
other AML collectives, remains to be determined [35].
Strong expression of lenalidomide’s target cereblon in the
leukemic blasts was rather associated with an unfavorable OS,
which has also been documented for gastric marginal zone
lymphomas [36], but has until now not been addressed in
myeloid neoplasms and may deserve attention in larger stud-
ies. Interestingly, all of the described effects were independent
from the genotype of the cereblon gene (CRBN), which is in
line with data from other IMiDs [23].
Our study has several shortcomings. We were not able to
investigate the bone marrow samples of all patients included
in the HOVON103 AML/SAKK 30/10 study due to lacking
material and therefore the sample size is very limited. Due to
the random distribution of cases, there was an imbalance of
the assigned treatment arms among the AML categories.
Finally, the observed beneficial effect of the addition of
lenalidomide was present only in a subgroup of patients, i.e.,
AML-MRC, which although being a WHO category, is yet a
post-hoc subcohort from the perspective of the initial clinical
trial design [12].
Observable on a small number of patients, addition of
lenalidomide led to a perceptible but not significant increase
of PFS in patients with AML-MRC, a category characterized
by a poor prognosis and often complex karyotypes. Our
Ann Hematol (2021) 100:1169–1179 1177
findings are in keeping with encouraging results in the litera-
ture, showing on the one hand a direct anti-leukemic effect of
lenalidomide, and, on the other hand, an important immune-
activating impact on the tumor microenvironment. We think
that our observations also highlight the importance of taking
the WHO defined subentities into consideration when design-
ing clinical trials in AML.
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